SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-20-046585
Filing Date
2020-10-16
Accepted
2020-10-16 07:00:26
Documents
6
Period of Report
2020-12-01
Effectiveness Date
2020-10-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A eypt-def14a_20201201.htm DEF 14A 385819
2 GRAPHIC g1vx2b0scqss000005.jpg GRAPHIC 76845
3 GRAPHIC g1vx2b0scqss000003.jpg GRAPHIC 4629
4 GRAPHIC g1vx2b0scqss000004.jpg GRAPHIC 90131
5 GRAPHIC g1vx2b0scqss000002.jpg GRAPHIC 2913
6 GRAPHIC g1vx2b0scqss000001.jpg GRAPHIC 4729
  Complete submission text file 0001564590-20-046585.txt   634653
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 201242772
SIC: 3826 Laboratory Analytical Instruments